Page last updated: 2024-10-17

bupropion and Neoplasms

bupropion has been researched along with Neoplasms in 18 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions."9.41Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023)
"For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life."9.14A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010)
"This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life."9.12An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006)
"This is the first report that shows bupropion SR can reduce fatigue in cancer patients."7.72Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004)
"Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6."6.94Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020)
"Nicotine dependence is a significant addiction with many health consequences."6.47Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy. ( Grief, SN, 2011)
"This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions."5.41Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023)
"For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life."5.14A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010)
"This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life."5.12An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006)
" This study evaluated the feasibility, safety, and effect on cessation of varenicline for smoking cessation in patients with cancer."3.85The use of varenicline to treat nicotine dependence among patients with cancer. ( Blazekovic, S; Brubaker, TR; Hitsman, B; Hole, A; Kalhan, R; Langer, C; Leone, F; Patel, J; Price, S; Schnoll, R; Veluz-Wilkins, A; Wileyto, EP, 2017)
"This is the first report that shows bupropion SR can reduce fatigue in cancer patients."3.72Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004)
" We also analyzed the adverse event profile differences between the medications."3.11Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. ( Beneventi, D; Blalock, JA; Chaftari, P; Cinciripini, PM; Cui, Y; Gonzalez, R; Karam-Hage, M; Kypriotakis, G; Robinson, JD; Tayar, J, 2022)
"Sonidegib dosed orally at 800 mg QD (higher than the Food and Drug Administration-approved dose) did not impact the PK or pharmacodynamics of warfarin (CYP2C9 probe substrate) or the PK of bupropion (CYP2B6 probe substrate)."3.01The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. ( Amaravadi, RK; Britten, CD; Chung, V; Gutierrez, M; Lee, JJ; Lewis, LD; LoRusso, P; Ness, DB; O'Rourke, MA; Olszanski, AJ; Perez, R; Pooler, DB; Ravichandran, S; Sarantopoulos, J; Shapiro, GI; Squittieri, N; Vaishampayan, U, 2021)
"Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6."2.94Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020)
"Among smokers recently diagnosed with cancer in 2 National Cancer Institute-designated Comprehensive Cancer Centers, sustained counseling and provision of free cessation medication compared with 4-week counseling and medication advice resulted in higher 6-month biochemically confirmed quit rates."2.94Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial. ( Borderud, S; Cooley, ME; de León-Sanchez, S; Friedman, ER; Gonzalez, I; Holland, S; Hyland, KA; Irwin, KE; Kwon, D; Levy, DE; Malloy, L; Miller-Sobel, J; Muzikansky, A; O'Brien, M; Ostroff, JS; Park, ER; Partridge, AH; Perez, GK; Peterson, L; Pirl, WF; Ponzani, C; Rabin, J; Regan, S; Rigotti, NA; Sprunck, K; Temel, JS; Whitlock, CW, 2020)
"Many cancer patients continue to smoke postdiagnosis, which is associated with poorer clinical outcomes."2.76Predictors of smoking cessation among cancer patients enrolled in a smoking cessation program. ( Langer, C; Leone, F; Martinez, E; Miyamoto, C; Schnoll, RA, 2011)
"Nicotine dependence is a significant addiction with many health consequences."2.47Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy. ( Grief, SN, 2011)
"Smokers with cancer do not smoke by life-style choice but because they are highly addicted and are suffering from a chronic relapsing disease: tobacco dependence, which justifies intensive medical management."1.38[Methods and results of smoking cessation in cancer smoker's]. ( Dautzenberg, B, 2012)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.56)18.7374
1990's0 (0.00)18.2507
2000's3 (16.67)29.6817
2010's9 (50.00)24.3611
2020's5 (27.78)2.80

Authors

AuthorsStudies
Robinson, JD1
Karam-Hage, M1
Kypriotakis, G1
Beneventi, D1
Blalock, JA1
Cui, Y1
Gonzalez, R1
Tayar, J1
Chaftari, P1
Cinciripini, PM1
Correa-Morales, JE1
Cuellar-Valencia, L1
Mantilla-Manosalva, N1
Quintero-Muñoz, E1
Iriarte-Aristizábal, MF1
Giraldo-Moreno, S1
Rodríguez-Campos, LF1
Salehifar, E1
Azimi, S1
Janbabai, G1
Zaboli, E1
Hendouei, N1
Saghafi, F1
Borhani, S1
Pooler, DB1
Ness, DB1
Sarantopoulos, J1
Squittieri, N1
Ravichandran, S1
Britten, CD1
Amaravadi, RK1
Vaishampayan, U1
LoRusso, P1
Shapiro, GI1
Olszanski, AJ1
Perez, R1
Gutierrez, M1
O'Rourke, MA1
Chung, V1
Lee, JJ1
Lewis, LD1
Park, ER1
Perez, GK1
Regan, S1
Muzikansky, A1
Levy, DE1
Temel, JS1
Rigotti, NA1
Pirl, WF1
Irwin, KE1
Partridge, AH1
Cooley, ME1
Friedman, ER1
Rabin, J1
Ponzani, C1
Hyland, KA1
Holland, S1
Borderud, S1
Sprunck, K1
Kwon, D1
Peterson, L1
Miller-Sobel, J1
Gonzalez, I1
Whitlock, CW1
Malloy, L1
de León-Sanchez, S1
O'Brien, M1
Ostroff, JS1
Ashrafi, F1
Mousavi, S1
Karimi, M1
Lin, CY1
Lee, CH1
Chuang, YH1
Lee, JY1
Chiu, YY1
Wu Lee, YH1
Jong, YJ1
Hwang, JK1
Huang, SH1
Chen, LC1
Wu, CH1
Tu, SH1
Ho, YS1
Yang, JM1
Barsevick, AM1
Irwin, MR1
Hinds, P1
Miller, A1
Berger, A1
Jacobsen, P1
Ancoli-Israel, S1
Reeve, BB1
Mustian, K1
O'Mara, A1
Lai, JS1
Fisch, M1
Cella, D1
Boušová, I1
Skálová, L1
Souček, P1
Matoušková, P1
Price, S1
Hitsman, B1
Veluz-Wilkins, A1
Blazekovic, S1
Brubaker, TR1
Leone, F3
Hole, A1
Wileyto, EP2
Langer, C3
Kalhan, R1
Patel, J1
Schnoll, R1
Schnoll, RA2
Martinez, E2
Tatum, KL1
Weber, DM1
Kuzla, N1
Glass, M1
Ridge, JA1
Miyamoto, C2
Grief, SN1
Dautzenberg, B1
Cullum, JL1
Wojciechowski, AE1
Pelletier, G2
Simpson, JS2
Moss, EL1
Forsyth, P1
Tucker, WE1
Vainio, H1
Weiderpass, E1
Kleihues, P1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors[NCT01769768]Phase 1114 participants (Actual)Interventional2013-04-30Completed
Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial[NCT01871506]303 participants (Actual)Interventional2013-09-30Completed
Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306]60 participants (Anticipated)Interventional2023-05-17Recruiting
Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329]80 participants (Anticipated)Interventional2018-05-13Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cost-effectiveness

The cost of the standard of care treatment and the cost of the intensive treatment. (NCT01871506)
Timeframe: 6 months

Interventiondollars (Mean)
Standard Treatment (ST)638
Intensive Treatment1144

Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months

Number of participants with7 -day point-prevalence tobacco abstinence at 3-month follow-up, assessed by biochemically confirmed saliva cotinine (<15 ng/ml76, 82) or <10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT (NCT01871506)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Standard Treatment (ST)28
Intensive Treatment (IT)46

Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months

Number of participants with 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (<15 ng/ml76, 82) or <10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT (NCT01871506)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Standard Treatment (ST)29
Intensive Treatment (IT)51

Number of Participants With Continuous Tobacco Abstinence

Number of Participants with Continuous tobacco abstinence (between quit and follow-up) at 3 & 6 months (NCT01871506)
Timeframe: 3 months to 6 months

InterventionParticipants (Count of Participants)
Standard Treatment26
Intensive Treatment)43

Number of Participants With Self-reported 7-day Point Prevalence.

Number of Participants with Self-reported smoking abstinence of at least 7 days (NCT01871506)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Standard Treatment (ST)42
Intensive Treatment (IT)54

Number of Participants With Sustained Tobacco Abstinence

Number of Participants with Biochemically confirmed repeated point prevalence abstinence at 3 & 6 months (NCT01871506)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Standard Treatment (ST)17
Intensive Treatment (IT)35

The Number of IT Participants Who Took 1-2 4-week Refills

The number of intervention participants who took 1-2 4-week refills of smoking cessation medication (NCT01871506)
Timeframe: Treatment Initiation to 6 Month Follow-up

InterventionParticipants (Count of Participants)
Intensive Treatment (IT)87

The Number of IT Participants Who Took 1-3 Monthly Booster Sessions

The number of IT participants who took 1-3 monthly booster sessions of smoking cessation counseling (NCT01871506)
Timeframe: Treatment Initiation to 6 Month Follow-up

InterventionParticipants (Count of Participants)
Intensive Treatment (IT)99

The Number of IT Participants Who Used Smoking Cessation Counseling

The number of intervention participants who used smoking cessation counseling during the study (Y/N) (NCT01871506)
Timeframe: Treatment Initiation to 6 Month Follow-up

InterventionParticipants (Count of Participants)
Intensive Treatment (IT)153

The Number of IT Participants Who Used Smoking Cessation Pharmacotherapy

The number of IT participants who used 1) smoking cessation pharmacotherapy (Y/N dispensed) 2) smoking cessation counseling (Y/N), 3) 1-2 4-week refills, 4) took 1-3 monthly booster sessions. (NCT01871506)
Timeframe: Treatment Initiation to 6 month follow-up

InterventionParticipants (Count of Participants)
Intensive Treatment (IT)122

Reviews

4 reviews available for bupropion and Neoplasms

ArticleYear
Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review.
    Journal of pain and symptom management, 2023, Volume: 65, Issue:1

    Topics: Adult; Bupropion; Fatigue; Humans; Neoplasms

2023
The modulation of carbonyl reductase 1 by polyphenols.
    Drug metabolism reviews, 2015, Volume: 47, Issue:4

    Topics: Alcohol Oxidoreductases; Animals; Bupropion; Butanones; Butyrophenones; Daunorubicin; Doxorubicin; G

2015
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy.
    Primary care, 2011, Volume: 38, Issue:1

    Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Huma

2011
Smoking cessation in cancer prevention.
    Toxicology, 2001, Sep-14, Volume: 166, Issue:1-2

    Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Bupropion; Humans; Neoplasms; Risk Facto

2001

Trials

7 trials available for bupropion and Neoplasms

ArticleYear
Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center.
    The American journal on addictions, 2022, Volume: 31, Issue:3

    Topics: Bupropion; Humans; Neoplasms; Smoking; Smoking Cessation; Tobacco Smoking; Tobacco Use Cessation Dev

2022
Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial.
    BMC cancer, 2020, Feb-27, Volume: 20, Issue:1

    Topics: Adult; Aged; Bupropion; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S

2020
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:3

    Topics: Administration, Oral; Area Under Curve; Biphenyl Compounds; Bupropion; Drug Interactions; Humans; Ne

2021
Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial.
    JAMA, 2020, 10-13, Volume: 324, Issue:14

    Topics: Aged; Bupropion; Cotinine; Counseling; Decision Support Techniques; Female; Humans; Male; Middle Age

2020
A bupropion smoking cessation clinical trial for cancer patients.
    Cancer causes & control : CCC, 2010, Volume: 21, Issue:6

    Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Bupropion; Depression; Depressi

2010
Predictors of smoking cessation among cancer patients enrolled in a smoking cessation program.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:5

    Topics: Behavior Therapy; Bupropion; Female; Humans; Male; Middle Aged; Neoplasms; Nicotine; Placebos; Progn

2011
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
    Psycho-oncology, 2006, Volume: 15, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cohort Studies; Delayed-Action Preparati

2006

Other Studies

7 other studies available for bupropion and Neoplasms

ArticleYear
Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study
    Asian Pacific journal of cancer prevention : APJCP, 2018, Jun-25, Volume: 19, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action

2018
Membrane protein-regulated networks across human cancers.
    Nature communications, 2019, 07-16, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bupropion; Cell Line, Tumor; Datasets as Topic; F

2019
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
The use of varenicline to treat nicotine dependence among patients with cancer.
    Psycho-oncology, 2017, Volume: 26, Issue:10

    Topics: Adult; Benzazepines; Bupropion; Counseling; Feasibility Studies; Female; Humans; Male; Middle Aged;

2017
[Methods and results of smoking cessation in cancer smoker's].
    Bulletin du cancer, 2012, Volume: 99, Issue:11

    Topics: Benzazepines; Bupropion; Humans; Neoplasms; Nicotinic Agonists; Quinoxalines; Secondary Prevention;

2012
Bupropion sustained release treatment reduces fatigue in cancer patients.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:2

    Topics: Adjustment Disorders; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiet

2004
Preclinical toxicology of bupropion: an overview.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2

    Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents; Bupropion; Central Nervous System; Chem

1983